Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1091327

	registered interest
	date	19/03/2019
	answering body	Treasury
	answering dept id	14
	answering dept short name	Treasury
	answering dept sort name	Treasury
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Chancellor of the Exchequer, what steps his Department is taking to equalize VAT between privately-owned companies and the NHS in relation to pharmaceutical procurement.
	tabling member constituency	Portsmouth South
	tabling member printed	Stephen Morgan
	uin	234250
	answer	answer is ministerial correction date of answer 22/03/2019 answer text VAT is charged on the sale of pharmaceutical products, regardless of whether the purchaser is a privately-owned company or the NHS. The central funding the NHS receives from the Treasury is intended to cover the costs NHS bodies incur in providing free healthcare, including VAT costs. answering member constituency Central Devon answering member printed Mel Stride question first answered 22/03/2019 14:06:40 answering member 3935 label Biography information for Mel Stride
	tabling member	4653 label Biography information for Stephen Morgan

1124979

	registered interest
	date	07/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the administration of medicines in NHS trusts.
	tabling member constituency	St Austell and Newquay
	tabling member printed	Steve Double
	uin	251361
	answer	answer is ministerial correction date of answer 15/05/2019 answer text <p>Work has commenced on a variety of projects to help improve the administration of medicines in National Health Service trusts.</p><p>Following the announcement of £75 million of funding for ePrescribing and Medicines Administration (ePrescribing or ePMA) systems, work has commenced to accelerate the uptake and implementation across the NHS. Funding was provided to 13 trusts in 2018/19 all of whom have now commenced work. Applications for the second wave of funding have been received – a total of 48 bids are currently being reviewed for 2019/20 funding. A further round of funding is also planned for 2020/21.</p><p>Additionally, the Global Digital Exemplar programme is providing funding to support the roll-out of new, integrated technologies including ePrescribing and closed loop medicines administration and will share their learning as they make progress.</p><p>The sites that have led the way with closed loop medicines administration have provided valuable learning for what is a relatively new approach to support this process in England. Early work is demonstrating a positive impact on medication related administration error.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 251362 question first answered 15/05/2019 15:49:08 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4452 label Biography information for Steve Double

843678

	registered interest
	date	19/02/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the announcement by NHS England on 18 December 2017 on new specialised treatments, what estimate he has made of the annual expenditure for new medicines approved for funding as a result of the November 2017 prioritisation process.
	tabling member constituency	Reigate
	tabling member printed	Crispin Blunt
	uin	128019
	answer	answer is ministerial correction date of answer 27/02/2018 answer text <p>With reference to the announcement made by NHS England on 18 December 2017 on new specialised treatments for funding as a result of the November 2017 prioritisation process, NHS England estimate that in excess of £3 million annual expenditure for new medicines was approved.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/02/2018 17:08:31 answering member 4067 label Biography information for Steve Brine
	tabling member	104 label Biography information for Crispin Blunt

1581686

	registered interest
	date	30/01/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the link between the use of innovative medicines by the NHS and (1) the placement of clinical trials in the UK, (2) patient outcomes, and (3) employment levels in the life sciences industry in the UK.
	tabling member printed	Lord Warner
	uin	HL5234
	answer	answer is ministerial correction date of answer 09/02/2023 answer text <p>Whilst we have made no specific assessment, the Government’s Life Sciences Vision sets out our ambition to stimulate the United Kingdom’s life sciences sector. The vision commits the Government to supporting the National Health Service to test, purchase and spread innovative technologies more effectively, so that cutting-edge science and innovations can be embedded widely across the NHS as early as possible, and rapidly adopted in the rest of the world. We are working with industry and system partners to make the NHS the country’s highest driver of innovation.</p> answering member printed Lord Markham question first answered 09/02/2023 12:20:32 answering member 4948 label Biography information for Lord Markham
	tabling member	1732 label Biography information for Lord Warner

1047672

	registered interest
	date	24/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to his Department's informal consultation with stakeholder representative bodies on changes to the Human Medicines Regulation 2012 to ensure the continuity of supply of medicines including in a no deal Brexit, published on 14 January 2019, whether any responses to that consultation raised concern about the consultation process; and if his Department will publish the responses to that consultation.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	212366
	answer	answer is ministerial correction date of answer 31/01/2019 answer text <p>Whilst there was no statutory obligation to consult on these changes to the Human Medicines Regulations 2012, the Department engaged with stakeholder representative bodies representing pharmacists, doctors, patient groups and the pharmaceutical industry about its proposals. As part of that engagement, it also conducted a short written consultation. Some respondents raised concerns about the short duration of the written consultation. In response, the Department has included a review clause in the legislation, putting an obligation on the Department to review the operation of the legislation, one year after issuing the first protocol. In addition, in the Explanatory Memorandum, the Department has committed to conducting a consultation as part of that review.</p><p> </p><p>The Explanatory Memorandum also reflects the main concerns raised in the consultation. Because the consultation was not a public one, the Department’s response to the consultation has not been published but has been sent to all respondents and is available on request.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 31/01/2019 16:19:22 answering member 4067 label Biography information for Steve Brine
	tabling member	4249 label Biography information for Anne Marie Morris

1138920

	registered interest
	date	15/07/2019
	answering body	Scotland Office
	answering dept id	2
	answering dept short name	Scotland
	answering dept sort name	Scotland
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Scotland, what recent discussions he has had with the Secretary of State for Health and Social Care on the supply of medicine to Scotland in the event that the UK leaves the EU without an agreement.
	tabling member constituency	Coatbridge, Chryston and Bellshill
	tabling member printed	Hugh Gaffney
	uin	277259
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>While the Government believes that leaving the EU with a deal is the best outcome, leaving without a deal remains the legal default at the end of the extension period on 31 October 2019. As a responsible Government, we have been preparing to minimise any disruption in the event of a no-deal scenario and are continuing with these preparations.</p><p> </p><p>The supply of critical ‘category 1’ goods, including medicines and medical products, remains an essential element of the Government’s no-deal contingency planning. The Department of Health and Social Care is working with the Devolved Administrations to support the continuity of medical supplies and medicines for the whole of the UK, and will continue to engage with devolved administration officials and Ministers to prepare for a potential ‘no-deal’ on 31 October. The Government has also set out in a Written Ministerial Statement an update on its preparations for a no-deal scenario on 26 June 2019 (<a href="https://www.parliament.uk/business/publications/written-questions-answers-statements/written-statement/Commons/2019-06-26/HCWS1661/" target="_blank">HCWS1661</a>).</p><p> </p><p> </p><p> </p> answering member constituency Dumfriesshire, Clydesdale and Tweeddale answering member printed David Mundell question first answered 23/07/2019 11:39:43 answering member 1512 label Biography information for David Mundell
	tabling member	4614 label Biography information for Hugh Gaffney

1675672

	registered interest
	date	05/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 31 July to Question HL9573 in the House of Lords on NHS: Drugs, what assessment the has made of the adequacy of the (a) complaints system, (b) performance and (c) safety of homecare medicines services.
	tabling member constituency	Kingston upon Hull West and Hessle
	tabling member printed	Emma Hardy
	uin	5388
	answer	answer is ministerial correction date of answer 11/12/2023 answer text <p>While no assessment has been made by the Department, the House of Lords Public Services Select Committee published its report on Homecare Medicines Services on 16 November 2023. NHS England has also been carrying out a desktop exercise to review homecare medicines services. The next steps are to bring together data from the desktop exercise with the House of Lords inquiry report recommendations to shape a programme of work on homecare medicines. The Department is carefully considering all the conclusions and recommendations made in the report and will respond in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 11/12/2023 15:28:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4645 label Biography information for Emma Hardy

1148861

	registered interest
	date	14/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Explanatory Memorandum to The Human Medicines (Amendment) Regulations 2019, 7.12, whether in the event of a Serious Shortage Protocol being issued for immunosuppressant medicines patients would always be referred back to the prescriber for any decision on their treatment before any therapeutic or generic alternative is supplied.
	tabling member constituency	High Peak
	tabling member printed	Ruth George
	uin	326
	answer	answer is ministerial correction date of answer 22/10/2019 answer text <p>While Serious Shortage Protocols (SSP) in England have the scope to cover all medicines and appliances that are on a National Health Service prescription in primary care, including immunosuppressant medicines, it is clear that an SSP for therapeutic or generic equivalents will not necessarily be suitable for all medicines and patients. For example, where medicines need to be prescribed by brand for clinical reasons, which may be the case for certain immunosuppressant medicines. In these cases, patients would always be referred back to the prescriber for any decision about their treatment before any alternative is supplied.</p><p>Any protocol would however only be introduced if clinicians with expertise in the relevant area think it is appropriate. So, if an SSP for an immunosuppressant medicine was under consideration, this would be agreed with, for example, transplant specialists or other relevant clinicians. Pharmacists will have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate or the patient should be referred to their prescriber.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 22/10/2019 11:21:30 answering member 4380 label Biography information for Jo Churchill
	tabling member	4662 label Biography information for Ruth George

1060592

	registered interest
	date	13/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many weeks’ worth of medicines the Government has asked pharmaceutical companies to stockpile as part of preparations for the UK leaving the EU without a deal; and how his Department decided on that period of duration.
	tabling member constituency	Enfield, Southgate
	tabling member printed	Bambos Charalambous
	uin	220998
	answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>We understand that breast cancer drugs are vitally important to many people in this country. Our ‘no deal’ European Union exit contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the EU/European Economic Area (EEA), to ensure that the supply of breast cancer drugs and other essential medicines to patients is not disrupted.</p><p> </p><p>In August 2018, the Department wrote to all pharmaceutical companies that supply prescription-only and pharmacy medicines to the UK that come from or via the EU/EEA asking them to ensure a minimum of six weeks additional supply in the UK, over and above existing business-as-usual buffer stocks, by 29 March 2019 in a ‘no deal’ scenario. The duration of the stockpiling requirement was based on the Government’s reasonable worst-case scenario border disruption planning assumptions.</p><p> </p><p>We also recognise that certain medicines with short shelf lives, including medical radioisotopes, cannot be reasonably stockpiled. Where these medicines are imported from the EU or EEA, we have asked that suppliers ensure in advance plans to air freight these medicines from the EU in the event of the no deal exit.</p><p> </p><p>The Department is unable to discuss specific medicines because to we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme, in order to reassure participating companies. This means not introducing information about a specific company, medicine, or a supply route into the public domain or to a third party.</p> answering member constituency Wimbledon answering member printed Stephen Hammond grouped question UIN 221000 question first answered 18/02/2019 15:19:26 answering member 1585 label Biography information for Stephen Hammond
	tabling member	4610 label Biography information for Bambos Charalambous

1330995

	registered interest
	date	08/06/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government how many planned discontinuation notices for the supply of medicines they have received as of 1 June 2021; and what steps they are taking to mitigate such notices.
	tabling member printed	Lord Empey
	uin	HL848
	answer	answer is ministerial correction date of answer 21/06/2021 answer text <p>We regularly receive notifications of discontinuations and possible discontinuations from suppliers, as well as information about shortages and potential shortages caused by a whole variety of reasons and numbers change daily. We are unable to provide this information as it is commercially sensitive.</p><p> </p><p>The Department has well-established procedures to deal with medicines shortages and discontinuations and works with a range of stakeholders to ensure that the risks to patients are minimised when they do arise. Not all notifications will lead to the discontinuation of a medicine or a shortage in the market.</p> answering member printed Lord Bethell question first answered 21/06/2021 11:59:21 answering member 4708 label Biography information for Lord Bethell
	tabling member	4216 label Biography information for Lord Empey